Early intraretinal fluid volume dynamics after switching from aflibercept 2 mg to faricimab in diabetic macular oedema
Open Access
- 14 November 2026
- journal article
- Published by Wiley in Acta Ophthalmologica
Abstract
Purpose: To evaluate intraretinal fluid (IRF) volume dynamics after switching from aflibercept 2 mg to faricimab in eyes with diabetic macular oedema (DME), stratified by prior response to aflibercept. Methods: This retrospective study at the Medical University of Vienna included patients with DME who were switched from aflibercept 2 mg to faricimab. IRF dynamics and central subfield thickness (CST) were assessed after two faricimab injections. Eyes were categorized as prior responders or non‐responders based on their anatomical response to the last aflibercept injection (≥20% CST reduction or CST ≤250 μm). Optical coherence tomography (OCT)–derived CST and quantitative IRF volumes were analysed at baseline and after two faricimab injections. Associations between CST and IRF changes were evaluated. Results: Fifty‐eight eyes of 45 patients (mean age 65.3 ± 10 years) were included, with 56 eyes previously treated with aflibercept. After two faricimab injections (mean follow‐up 10.1 ± 2.2 weeks), CST and total IRF volume decreased significantly ( p < 0.0001). CST reduction was strongly associated with IRF reduction in the central millimetre (estimate 1.00 [0.73–1.28], p < 0.0001), but less so with total IRF volume (estimate 0.22 [0.17–0.28], p < 0.0001). Responders ( n = 28) showed greater CST reduction compared to non‐responders (−105.6 ± 123.9 μm vs. −27.3 ± 60.1 μm; p = 0.0003) and lower total IRF volume after treatment ( p = 0.029), with more consistent regional improvements. Non‐responders showed smaller but still significant IRF reductions. Conclusions: Switching from aflibercept 2 mg to faricimab resulted in significant reductions in CST and IRF volumes after two injections with a more pronounced effect in previous responders. While CST closely reflected central changes, its weaker association with total IRF reduction indicates that quantitative fluid assessment may further refine evaluation of treatment response and retreatment decisions.This publication has 26 references indexed in Scilit:
- AI-based fluid quantification in neovascular age-related macular degeneration and diabetic macular edema treated with faricimab – a real-life studyGraefe's Archive for Clinical and Experimental Ophthalmology, 2025
- Correlation of point-wise retinal sensitivity with localized features of diabetic macular edema using deep learningCanadian Journal of Ophthalmology, 2025
- Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th editionDiabetes Research and Clinical Practice, 2019
- Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular EdemaOphthalmology, 2019
- Early Response to Anti–Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol TAmerican Journal of Ophthalmology, 2018
- Fully Automated Detection and Quantification of Macular Fluid in OCT Using Deep LearningOphthalmology, 2018
- Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision ImpairmentJAMA Ophthalmology, 2018
- Early and Long-Term Responses to Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I DataAmerican Journal of Ophthalmology, 2016
- A Systematic Correlation of Angiography and High-Resolution Optical Coherence Tomography in Diabetic Macular EdemaOphthalmology, 2009
- Relationship between Optical Coherence Tomography–Measured Central Retinal Thickness and Visual Acuity in Diabetic Macular EdemaOphthalmology, 2007